ETHealthworld.com brings latest subhanu saxena news, views and updates from all top sources for the Indian Health industry.

Jefferies downgraded Syngene to 'underperform' and slashed price target to Rs 480 from Rs 660; JPMorgan downgraded Cipla to ...

Cipla shares traded lower after the drugmaker reported a sharp year-on-year decline in December-quarter profit, prompting ...

Bata India, Indian Hotels, IGL, MGL, Just Dial, Kalyan Jewellers, Jubilant FoodWorks, Oberoi Realty, Mankind Pharma and ...

Drugmakers Sun Pharma, Cipla, Zydus and Graviti Pharmaceuticals are recalling different products in the U.S., most of them over manufacturing issues.

Net Sales at Rs 7,074.48 crore in December 2025 up 0.02% from Rs. 7,072.97 crore in December 2024. Quarterly Net Profit at Rs. 675.80 crore in December 2025 down 56.97% from Rs. 1,570.51 crore in ...

Cipla share price falls over 2% after weak Q3FY26 results; profit drops 57% YoY, brokerages cut targets citing US headwinds.

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ahead of the market with our in-depth coverage of Cipla, including: Last ...

The shares of Indian pharmaceutical majors Sun Pharma and Cipla will be in focus today. According to the US Food and Drug Administration, both pharma companies are recalling products in the US due to ...

Several brokerages downgraded Cipla following a weaker-than-expected December quarter performance, citing softness in US ...

In light of Cipla's weak Q3 earnings, brokerages including Goldman Sachs, HSBC, and BofA have all cut target price on the ...

Sun Pharma and Cipla are recalling specific products in the US due to manufacturing issues, as reported by the US Food and Drug Administration.